BeOne
NEWS
Here’s a look at the two drugs that had dates this week but were approved early and are now on the market.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.
The drug, a checkpoint inhibitor, met the primary endpoint of improved progression-free survival at the planned interim analysis.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Almost one month after BeiGene’s Bruton’s kinase inhibitor Brukinsa won accelerated approval for mantle cell lymphoma, the company reported the drug failed to hit the mark in a late-stage trial assessing the drug as a treatment for Waldenström’s macroglobulinemia.
BeiGene, Ltd. announced that the company will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY.
It is the first BeiGene-discovered drug to be approved.
Amgen announced that it has agreed to acquire a 20.5% stake in BeiGene for approximately $2.7 billion in cash and concurrently has entered into a strategic collaboration pursuant to which BeiGene will commercialize XGEVA®, KYPROLIS® and BLINCYTO® in China and advance 20 medicines from Amgen’s innovative oncology pipeline in China and globally.
“This strategic collaboration with BeiGene will enable Amgen to serve significantly more patients by expanding our presence in the world’s most populous country,” said Robert A. Bradway, Amgen’s chairman and chief executive officer.
JOBS
IN THE PRESS